MoonLake Immunotherapeutics - Ordinary Shares - Class A Live Stock Price Today, Share Analysis and Chart

Name: MoonLake Immunotherapeutics - Ordinary Shares - Class A: Is Infosys Ltd. worth buying?
Item: MoonLake Immunotherapeutics - Ordinary Shares - Class A
Rating: 1.52375
Author: Trendlyne DVM scores

about

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibit...

52.35 -2.12 (-3.89%)

New 52W High in past week

339.2K

XNAS Volume

XNAS 29 Jul, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for MoonLake Immunotherapeutics - Ordinary Shares - Class A is on 07 Aug 2025 for the purpose of MoonLake Immunotherapeutics Second Quarter Earnings Results for 2025 See details